Literature DB >> 19638592

Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention.

Katarzyna Franciszkiewicz1, Audrey Le Floc'h, Abdelali Jalil, Frédéric Vigant, Thomas Robert, Isabelle Vergnon, Andrzej Mackiewicz, Karim Benihoud, Pierre Validire, Salem Chouaib, Christophe Combadière, Fathia Mami-Chouaib.   

Abstract

We have reported previously that the interaction of alpha(E)(CD103)beta(7) integrin, expressed on a CD8(+) tumor-infiltrating lymphocyte (TIL) clone but not on a peripheral blood lymphocyte (PBL) counterpart, with the epithelial marker E-cadherin on human lung tumor cells plays a crucial role in T-cell receptor-mediated cytotoxicity. We show here that both TIL and PBL clones are able to migrate toward autologous tumor cells and that chemokine receptor CCR5 is involved in this process. Adoptive transfer of the PBL clone in the cognate tumor engrafted in nonobese diabetic/severe combined immunodeficient mice and subsequent coengagement of T-cell receptor and transforming growth factor-beta1 receptor triggers CD103 expression on T-cell surface resulting in strong potentiation of antitumor lytic function. Moreover, interaction of alpha(E)beta(7) integrin with E-cadherin, but not lymphocyte function-associated antigen-1 with intercellular adhesion molecule-1, promotes CCR5 recruitment at the immunologic synapse formed between TIL and tumor cells, leading to inhibition of T-cell sensitivity to CCL5 chemotactic gradient. These results provide evidence for a role of tumor microenvironment, namely MHC class I-restricted antigen presentation and transforming growth factor-beta1 secretion, in regulating the effector phase of tumor-specific CTL response. They also suggest a unique role of CD103 in T-cell retention at the tumor site by a CCR5-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19638592     DOI: 10.1158/0008-5472.CAN-08-3571

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.

Authors:  Gabriela Schiechl; Bernhard Bauer; Ivan Fuss; Sven A Lang; Christian Moser; Petra Ruemmele; Stefan Rose-John; Markus F Neurath; Edward K Geissler; Hans-Jürgen Schlitt; Warren Strober; Stefan Fichtner-Feigl
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

2.  Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Authors:  Elise P Salerno; Sofia M Shea; Walter C Olson; Gina R Petroni; Mark E Smolkin; Chantel McSkimming; Kimberly A Chianese-Bullock; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2013-05-09       Impact factor: 6.968

3.  Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.

Authors:  Hélène Salmon; Katarzyna Franciszkiewicz; Diane Damotte; Marie-Caroline Dieu-Nosjean; Pierre Validire; Alain Trautmann; Fathia Mami-Chouaib; Emmanuel Donnadieu
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  CD8⁺ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung.

Authors:  Berber Piet; Godelieve J de Bree; Barbara S Smids-Dierdorp; Chris M van der Loos; Ester B M Remmerswaal; Jan H von der Thüsen; Jan M W van Haarst; Jan P Eerenberg; Anja ten Brinke; Wim van der Bij; Wim Timens; René A W van Lier; René E Jonkers
Journal:  J Clin Invest       Date:  2011-05-02       Impact factor: 14.808

5.  Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.

Authors:  Marit M Melssen; Walter Olson; Nolan A Wages; Brian J Capaldo; Ileana S Mauldin; Adela Mahmutovic; Ciara Hutchison; Cornelis J M Melief; Timothy N Bullock; Victor H Engelhard; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

6.  Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration.

Authors:  Tim Zimmermann; Markus Moehler; Ines Gockel; George G Sgourakis; Stefan Biesterfeld; Michaela Müller; Martin R Berger; Hauke Lang; Peter R Galle; Carl C Schimanski
Journal:  Int J Colorectal Dis       Date:  2010-04       Impact factor: 2.571

7.  T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins.

Authors:  Elise P Salerno; Walter C Olson; Chantel McSkimming; Sofia Shea; Craig L Slingluff
Journal:  Int J Cancer       Date:  2014-02-01       Impact factor: 7.396

8.  CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.

Authors:  Kechang Liu; Bryan A Anthony; Martha M Yearsly; Mehdi Hamadani; Alice Gaughan; Jiao-Jing Wang; Steven M Devine; Gregg A Hadley
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

Review 9.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

10.  Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.

Authors:  Toshiki Iwai; Masamichi Sugimoto; Namrata S Patil; Daniel Bower; Miho Suzuki; Chie Kato; Keigo Yorozu; Mitsue Kurasawa; David S Shames; Osamu Kondoh
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.